June 27, 2021 News
Indivumed Expands Cancer Drug Discovery Efforts
We are happy to share our recent GenomeWeb feature story and interview with CEO Prof. Dr. Hartmut Juhl and CBO Roald Forsberg, PhD as well as one of our partners Dr. David Kerr from University of Oxford talking about the launch of nRavel, Drug Discovery Efforts, Achievements and Goals. Thanks to GenomeWeb and Neil Versel for writing this piece.Read more
June 09, 2021 News
Indivumed becomes Certified Service Provider of the Spatial Transcriptomics technology by 10x Genomics
Indivumed became a “Certified Service Provider” of the Spatial Transcriptomics technology (Visium Spatial Gene Expression) by 10x Genomics. In combination with the high quality multi-omics tissue Indivumed offers the whole workflow for customer research projects.Read more
June 02, 2021 Press
Indivumed Launches nRavel™ AI Platform
Indivumed GmbH today announced the launch of nRavel™, a unique AI discovery platform for oncology and precision medicine. The platform combines IndivuType’s deep multi-omics data with elaborate disease models, high-powered automated Machine Learning tools, and a comprehensive suite of advanced analytics tools. Together this creates an unparalleled engine for generating new discoveries and insights into cancer biology.Read more
May 17, 2021 Press
Indivumed Joins KHR Biotec
Indivumed GmbH CEO Dr. Hartmut Juhl and University Medical Center Mainz Professor Krishnaraj Rajalingam today announced Indivumed will be joining the newly formed KHR Biotech GmbH – a spin-off biopharma company from University Mainz. The new company will combine Prof. Rajalingam’s research and scientific approach with Indivumed’s database and AI capabilities in order to bring new compounds targeting pertinent oncogenic signaling pathways into the clinical phase.Read more
To meet all your needs in cancer research and drug development we offer you a broad spectrum of high-quality biospecimen samples including clinical data.
To further support your efforts in personalized oncology we offer you an holistic range of clinical, laboratory, and research services.
Indivumed GmbH’s long-standing expertise is ISO 9001:2015-certified and includes the collection of biological samples and clinical data (Biobank), research service in the form of immunohistochemistry, analysis of signaling proteins, drug testing, establishment of primary cell cultures and molecular biology, bioinformatic and biomedical data analysis.
Download the ISO-Certificate
Discover more about Indivumed’s work and the future of personalized cancer medicine in the following lectures and videos.
The Challlenge and Importance of Standardizing Pre-Analytical Variables in Surgical Pathology Specimens for Clinical Care and Translational Research
Speaker: David Hicks, M.D.